Skip to main content
SpringerLink
Log in

Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung

Consensus paper on prophylaxis against RSV infection with Palivizumab and post-RSV respiratory tract disease

  • Konsensuspapiere
  • Published:
Monatsschrift Kinderheilkunde Zeitschrift für Kinder- und Jugendmedizin Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Abman SH, Ogle JW, Butler-Simon N et al. (1988) Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr 113: 826–830

    Article  PubMed  CAS  Google Scholar 

  2. Arnold SR, Wang EE, Law BJ et al. (1999) Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 18: 866–869

    Article  PubMed  CAS  Google Scholar 

  3. Boeckh M, Berrey MM, Bowden RA et al. (2001) Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 184: 350–354

    Article  PubMed  CAS  Google Scholar 

  4. Bont L, Steijn M, Van Aalderen WMC et al. (2004) Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 59: 512–516

    Article  PubMed  CAS  Google Scholar 

  5. Bramley AM, Vitalis TZ, Wiggs BR et al. (1999) Effects of respiratory syncytial virus persistence on airway responsiveness and inflammation in guinea-pigs. Eur Respir J 14: 1061–1067

    Article  PubMed  CAS  Google Scholar 

  6. Buckingham SC, Jafri HS, Bush AJ et al. (2002) A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185: 1222–1228

    Google Scholar 

  7. Cole PD, Suh JS, Stiles J et al. (2001) Benign outcome of RSV infection in children with cancer. Med Pediatr Oncol 37: 24–29

    Article  PubMed  CAS  Google Scholar 

  8. Döring G, Gusenleitner W, Belohradsky BH et al. (2006) The risk of respiratory syncytial virus-related hospitalizations in preterm infants of 29 to 35 weeks gestational age. Pediatr Infect Dis J 25: 1188–1190

    Article  Google Scholar 

  9. Ermers MJJ, Hoebee B, Hodemaekers HM et al. (2007) IL-13 genetic polymorphism identifies children with late wheezing after respiratory syncytial virus infection. J Allergy Clin Immunol 119: 1086–1091

    Article  PubMed  CAS  Google Scholar 

  10. Garcia DF, Hiatt PW, Jewell A et al. (2007) Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatr Pulmonol 42: 66–74

    Article  PubMed  Google Scholar 

  11. Greenough A, Broughton S (2005) Chronic manifestations of respiratory syncytial virus infection in premature infants. Pediatr Infect Dis J 24: S184–188

    Article  PubMed  Google Scholar 

  12. Henderson J, Hilliard TN, Sherriff A et al. and the ALSPAC Study Team (2005) Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunol 16: 386–392

    Article  PubMed  Google Scholar 

  13. Hiatt PW, Grace SC, Kozinetz CA et al. (1999) Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 103: 619–626

    Article  PubMed  CAS  Google Scholar 

  14. Horn SD, Smout RJ (2003) Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 143: S133–141

    PubMed  Google Scholar 

  15. Hu C, Wedde-Beer K, Auais A et al. (2002) Nerve growth factor and nerve growth factor receptors in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol 283: 494–502

    Google Scholar 

  16. Kim CK, Chung CY, Choi SJ et al. (2000) Bronchoalveolar lavage cellular composition in acute asthma and acute bronchiolitis. J Pediatr 137: 517–522

    Article  PubMed  CAS  Google Scholar 

  17. Kim CK, Kim SW, Park CS et al. (2003) Bronchoalveolar lavage cytokine profiles in acute asthma and acute bronchiolitis. J Allergy Clin Immunol 112: 64–71

    Article  PubMed  CAS  Google Scholar 

  18. King KA, Hu C, Rodriguez MM et al. (2001) Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 24: 101–107

    PubMed  CAS  Google Scholar 

  19. Kneyber MCJ, Steyerberg EW, de Groot R et al. (2000) Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatr 89: 654–660

    Article  PubMed  Google Scholar 

  20. Law BJ, Langley JM, Allen U et al. (2004) The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 23: 806–814

    Article  PubMed  Google Scholar 

  21. Lee KK, Hegele RG, Manfreda J et al. (2007) Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: the Canadian Asthma Primary Prevention Study. Pediatr Pulmonol 42: 290–297

    Article  PubMed  Google Scholar 

  22. Madhi SA, Schoub B, Simmank K et al. (2000) Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J Pediatr 137: 78–84

    Article  PubMed  CAS  Google Scholar 

  23. Malfroot A, Adam G, Ciofu O et al. for the ECFS Vaccination group (2005) Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 4: 77–87

    Article  PubMed  Google Scholar 

  24. McCormick J, Southern KW (2007) A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child 92: 87–88

    Article  PubMed  CAS  Google Scholar 

  25. MedImmune Inc. (2007) Synagis® (palivizumab) for intramuscular administration [online]. Available from URL: http://www.synagis.com/content/sitetools/synagis_pi.pdf [accessed 2007 Jul 8]

  26. Meert K, Heidemann S, Abella B et al. (1990) Does prematurity alter the course of respiratory syncytial virus infection? Crit Care Med 18: 1357–1359

    Article  PubMed  CAS  Google Scholar 

  27. Noble V, Murray M, Webb MS et al. (1997) Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 76: 315–319

    Article  PubMed  CAS  Google Scholar 

  28. Nuijten MJ, Wittenberg W, Lebmeier M (2007) Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis. Pharmacoeconomics 25: 55–71

    Article  PubMed  Google Scholar 

  29. Piedimonte G (2003) Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection. Pediatr Infect Dis J 22: S66–75

    Article  PubMed  Google Scholar 

  30. Piedimonte G, Renzetti G, Auais A et al. (2005) Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr Pulmonol 40: 285–291

    Article  PubMed  Google Scholar 

  31. Red Book® (2006) Report of the Committee on Infectious Diseases, 27th edn. Red Book; American Academy of Pediatrics, Elk Grove Village

  32. Resch B, Gusenleitner W, Müller W (2002) The impact of respiratory syncytial virus infection: a prospective study in hospitalized infants younger than 2 years. Infection 30: 193–197

    Article  PubMed  CAS  Google Scholar 

  33. Resch B, Berger A, Urlesberger B et al. (2004) Österreichische Empfehlungen zur RSV Prophylaxe bei Frühgeborenen mit Palivizumab – Update 2003. Monatschr Kinderheilkd 152: 223–224

    Google Scholar 

  34. Resch B, Pasnocht A, Gusenleitner W et al. (2005) Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29–36 weeks gestational age. J Infect 50: 397–403

    Article  PubMed  CAS  Google Scholar 

  35. Resch B, Gusenleitner W, Müller W et al. (2006) Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks. Eur J Clin Microbiol Infect Dis 25: 120–122

    Article  PubMed  CAS  Google Scholar 

  36. Resch B, Nuijten MJ, Lebmeier M et al. (2006) The cost-effectiveness of palivizumab in Austria. Value Health 9: A94

    Google Scholar 

  37. Sampalis JS (2003) Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 143: S150–156

    Article  PubMed  Google Scholar 

  38. Schauer U, Hoffjan S, Bittscheidt J et al. (2002) RSV bronchiolitis and risk of wheeze and allergic sensitisation in the first year of life. Eur Respir J 20:1277–1283

    Article  PubMed  CAS  Google Scholar 

  39. Schwarze J, O’Donnell DR, Rohwedder A et al. (2004) Latency and persistence of respiratory syncytial virus despite T cell immunity. Am J Respir Crit Care Med 169: 801–805

    Article  PubMed  Google Scholar 

  40. Sigurs N, Bjarnason R, Sigurbergsson F et al. (2000) Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 161: 1501–1507

    PubMed  CAS  Google Scholar 

  41. Sigurs N, Gustafsson PM, Bjarnason R et al. (2005) Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 171: 137–141

    Article  PubMed  Google Scholar 

  42. Simoes EAF, Groothuis JR, Carbonell-Estrany X et al., and the Palivizumab Long-Term Respiratory Outcomes Study Group (2007) Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 151: 34–42

    Article  PubMed  CAS  Google Scholar 

  43. Stein RT, Sherrill D, Morgan WJ et al. (1999) Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 354: 541–545

    Article  PubMed  CAS  Google Scholar 

  44. Sznajder M, Stheneur C, Albonico V et al.; General Pediatrics Group of the French Society of Pediatrics (2005) Respiratory development of 5- to 6-year-old children experiencing a first bronchiolitis episode before age one. Allergy Immunol 37: 392–396

    CAS  Google Scholar 

  45. Thomas NJ, Hollenbeak CS, Ceneviva GD et al. (2007) Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision tree model. J Pediatr Hematol Oncol 29: 227–232

    Article  PubMed  CAS  Google Scholar 

  46. Tortorolo L, Langer A, Polidori G et al. (2005) Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection. Am J Respir Crit Care Med 172: 233–237

    Article  PubMed  Google Scholar 

  47. Van Ewijk BE, Van der Zalm MM, Wolfs TFW et al. (2005) Viral respiratory infections in cystic fibrosis. J Cyst Fibros 4: 31–36

    Article  CAS  Google Scholar 

  48. Van Ewijk BE, Wolfs TFW, Aerts PC et al. (2007) RSV mediates Pseudomonas aeruginosa binding to cystic fibrosis and normal epithelial cells. Pediatr Res 61: 398–403

    Article  Google Scholar 

  49. Van Woensel JBM, Kimpen JLL, Sprikkelman AB et al. (2000) Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus. Pediatr Pulmonol 30: 92–96

    Article  Google Scholar 

  50. Wat D, Doull I (2003) Respiratory virus infections in cystic fibrosis. Paediatr Respir Rev 4: 172–177

    Article  PubMed  Google Scholar 

  51. Wenzel SE, Gibbs RL, Lehr MV et al. (2002) Respiratory outcome in high-risk children 7 to 10 years after prophylaxis with respiratory syncytial virus immunoglobulin. Am J Med 112: 627–633

    Article  PubMed  CAS  Google Scholar 

  52. Wilkesmann A, Ammann RA, Schildgen O et al., and the DSM RSV Ped Study Group (2007) Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 26: 485–491

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung/en hin: Honorare und Reisekostenübernahmen im Rahmen von Vorträgen zum Thema RSV und/oder Palivizumab von Fa. Abbott Ges.mbH erhalten.

Author information

Consortia

Österreichische Gesellschaft für Kinder- und Jugendheilkunde (ÖGKJ)

Additional information

Addendum zu den Empfehlungen der Österreichischen Gesellschaft für Kinder- und Jugendheilkunde zur Respiratory Syncytial Virus (RSV)-Prophylaxe [33]

Rights and permissions

Reprints and permissions

About this article

Cite this article

Österreichische Gesellschaft für Kinder- und Jugendheilkunde (ÖGKJ). Konsensuspapier zur Prophylaxe der RSV-Infektion mit Palivizumab und Post-RSV-Atemwegserkrankung. Monatsschr Kinderheilkd 156, 381–383 (2008). https://doi.org/10.1007/s00112-008-1722-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-008-1722-y

Search

Navigation